Cardiovascular risk factors: are they useful screening tests?

Slides:



Advertisements
Similar presentations
Medical Statistics Joan Morris Professor of Medical Statistics Goldsmiths Lecture 2014.
Advertisements

© Copyright 2009 by the American Association for Clinical Chemistry LOX Index, a Novel Predictive Biochemical Marker for Coronary Heart Disease and Stroke.
Key messages Stephen S Lim, et al. Lancet 2007; 370:
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Modern Management of Cholesterol in the High-Risk Patient.
Physical Activity Trends ä Healthy People 2010 goal is to increase daily physical activity by 30% in adults. ä As of now 60% of the population is not active.
National and subnational mortality effects of major metabolic risk factors and smoking in Iran: a comparative risk assessment Scientific Webinars Farzadfar.
Cardiovascular Disease Middlesbrough Update for Middlesbrough Scrutiny Committee 4 th November 2014 Dr Tanja Braun.
 Ischaemic heart disease reduces blood supply to the heart muscles and is one of the major cardiovascular diseases.
December 02 1 Vascular mortality: Age-specific hazard ratios for 20 mmHg lower usual SBP deaths at ages
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
Hazard ratio (& 95% CI) for 20 mmHg lower usual systolic BP
Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study  Dr Jack R W Brownrigg,
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
Hypertension November 2016
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Prospective Studies Collaboration Lancet 2009; 373:
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Copyright © 2007 American Medical Association. All rights reserved.
United States Preventive Services Task Force: Recommendations for ABPM
ELIGIBILITY: MRC/BHF Heart Protection Study
Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.
HDL cholesterol and cardiovascular risk Epidemiological evidence
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.
Risk factor thresholds: their existence under scrutiny
HDL cholesterol and cardiovascular risk
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Improving Chronic Care Management
Teaching Tool: Blood Pressure Classification
Progress and Promise in RAAS Blockade
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment 
Baseline characteristics of HPS participants by prior diabetes
The Hypertension in the Very Elderly Trial (HYVET)
Volume 375, Issue 9709, Pages (January 2010)
The results of the SHARP trial
Type 2 diabetes: Overlap of clinical conditions
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Cardiovascular disease: Leading cause of death
Prospective Studies Collaboration Lancet 2009; 373:
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Lowering of SBP by 20 mm Hg Reduces Cardiovascular Risk by Half
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies  Prospective Studies Collaboration  The.
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies 
Volume 375, Issue 9725, Pages (May 2010)
Potential mechanisms whereby statins may reduce the risk of stroke
Ratio of relative risks of heart disease and stroke associated with higher blood pressure, smoking, type I and II diabetes, and higher cholesterol in women.
Hypertension November 2016
Cause of death Treatment-arm events, % (n=45 054)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Baseline Characteristics of the Subjects*
Relative risk of a major coronary heart disease event (myocardial infarction incidence, fatal coronary heart disease, or coronary revascularization) for.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
The results of the SHARP trial
Associations between type of MI and incident HF
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Associations between walking pace (three groups) and all-cause  (A) cardiovascular disease (B) and cancer (C) mortality by physical activity level (meeting.
Hazard ratios, with 95% confidence intervals as floating absolute risks, as estimate of association between category of updated mean haemoglobin A1c concentration.
Associations between walking pace (three groups) and all-cause (A), cardiovascular disease (B) and cancer (C) mortality by age group (
Alcohol, Other Drugs, and Health: Current Evidence May–June 2019
HR for mortality in ischemic heart disease.
HR for myocardial infarction.
Forest plot showing survival c-statistics for selected models, applied to the testing cohort. Forest plot showing survival c-statistics for selected models,
Presentation transcript:

Cardiovascular risk factors: are they useful screening tests? Malcolm Law Wolfson Institute of Preventive Medicine Barts and The London School of Medicine

Mortality in Britain Ischaemic heart disease 130,000 deaths per year Stroke 63,000 deaths per year Together one third of all deaths

Average values of risk factors: present day and prehistoric values at age 60 Present Western Prehistoric Proportion of present Western below prehistoric average Systolic BP (mmHg) 145 110 <1% Serum cholesterol (mmol/l) 6.0 3.2 <1% Plasma homocysteine (mmol/l) 13.4 9.7 <10% Body mass index (kg/m2) 27 22 <10% Law & Wald BMJ 2002;324:1570-6 Ubbink J Nutr 1996;126:1254S-7S

Blood pressure and IHD in a meta-analysis of cohort studies Relative risk Usual diastolic BP (mmHg) MacMahon et al Lancet 1990

Blood pressure and stroke in a meta-analysis of cohort studies Relative risk Diastolic BP (mmHg) MacMahon et al Lancet 1990

Serum cholesterol and ischaemic heart disease Did not die of IHD Died of IHD DR = 15% FPR = 5% Serum cholesterol (mmol/l) BUPA cohort study

Blood pressure and ischaemic heart disease Did not die of IHD Died of IHD DR = 13% FPR = 5% Diastolic blood pressure (mmHg) BUPA cohort study

Serum homocysteine and ischaemic heart disease Did not die of IHD Died of IHD DR = 13% FPR = 5% Serum homocysteine (mmol/L) (log scale) BUPA cohort study

Blood pressure and stroke Did not die of stroke Died of stroke DR = 24% FPR = 5% Diastolic blood pressure (mmHg) BUPA cohort study

Systolic blood pressure 28% Ischaemic heart disease Disease concentration in the 10% of the population with the most extreme risk factor values Proportion of cases in the most extreme 10% Stroke Systolic blood pressure 28% Ischaemic heart disease Systolic blood pressure 21% Serum cholesterol 21% Plasma homocysteine 20% Body mass index 22% Law & Wald BMJ 2002;324:1570-6

Proportion of events detected for a 5% FPR Combining risk factors to screen for ischaemic heart disease events Proportion of events detected for a 5% FPR apoB (or LDL cholesterol) 17% apoB and systolic blood pressure (SBP) 22% apoB, SBP, apoA1, apo(a) 24% apoB, SBP, apoA1, apo(a), smoking 27% 3 measures of apoB, SBP, apoA, apo(a) + smoking 28% 3 measures of apoB, SBP, apoA1, apo(a) + smoking, family history 29% Wald et al Lancet 1994;343:75-9

Why combining risk factors is less effective than one would think? LDL cholesterol detects 17% of cases for 5% FPR Systolic BP also detects 17% of cases for 5% FPR

Why combining risk factors is less effective than one would think? LDL cholesterol detects 17% of cases for 5% FPR Systolic BP also detects 17% of cases for 5% FPR What proportion would be detected if we used both?

Why combining risk factors is less effective than one would think? LDL cholesterol detects 17% of cases for 5% FPR Systolic BP also detects 17% of cases for 5% FPR What proportion would be detected if we used both? 17% + (17% of 83%) = 31%

Why combining risk factors is less effective than one would think? LDL cholesterol detects 17% of cases for 5% FPR Systolic BP also detects 17% of cases for 5% FPR What proportion would be detected if we used both? 17% + (17% of 83%) = 31% But the FPR would no longer be 5% - it would be nearly 10%

Why combining risk factors is less effective than one would think? LDL cholesterol detects 17% of cases for 5% FPR Systolic BP also detects 17% of cases for 5% FPR What proportion would be detected if we used both? 17% + (17% of 83%) = 31% But the FPR would no longer be 5% - it would be nearly 10% This is what is often overlooked Keeping FPR at 5%, detect 22% instead of 17% for one alone

If you found a group with a very high risk few people are in it The paradox of risk If you found a group with a very high risk few people are in it so one misses most of the cases

Example Healthy man age 60 who: smokes cigarettes cholesterol in top 5% (7.6mmo/L) blood pressure in top 5% (175 mmHg systolic) Absolute risk of MI or stroke = 9% per year (12 fold increase) But prevalence of such men is 6 per 10,000 [Five GPs between them would have one]

The paradox of risk Annual risk of IHD event or stroke in men aged 60 Risk Detection Positive cut-off rate rate 0.25% 99% 98%

The paradox of risk Annual risk of IHD event or stroke in men aged 60 Risk Detection Positive cut-off rate rate 0.25% 99% 98% 0.5% 88% 73%

The paradox of risk Annual risk of IHD event or stroke in men aged 60 Risk Detection Positive cut-off rate rate 0.25% 99% 98% 0.5% 88% 73% 1% 52% 28%

The paradox of risk Annual risk of IHD event or stroke in men aged 60 Risk Detection Positive cut-off rate rate 0.25% 99% 98% 0.5% 88% 73% 1% 52% 28% 2% 16% 5%

The paradox of risk Annual risk of IHD event or stroke in men aged 60 Risk Detection Positive cut-off rate rate 0.25% 99% 98% 0.5% 88% 73% 1% 52% 28% 2% 16% 5% 4% 1% 0%

Groups with an annual risk of heart attack or stroke of 5% or more event rate (fatal or not) annual death rate Previous myocardial infarction 5% 10% Previous stroke 5% 10% Angina without MI 3% 6% Transient ischaemic attacks without stroke 2% 5% Law at al Arch Intern Med 2002;162:2405-10

Asking for a history of any of these disorders is a screening enquiry It has a detection rate of about 50% ond a low FPR

Proportion with such a history About half of deaths from heart disease and stroke occur in people with a history of a first non-fatal event Proportion with such a history MI stroke Men aged 60 7% 3% 70 15% 7% Women aged 60 4% 2% 70 5% 3% Health Survey for England

In people with no history of disease age alone is the best screening test age cut-off 55 years - detection rate 94% positive rate = 23%

Conclusions Cardiovascular risk factors are important aetiologically Lowering them can greatly reduce risk But they are poor screening tests - they do not usefully discriminate between people who will and will not have an ischaemic heart disease event or stroke The best screening test is the presence of existing disease. In people without existing disease it is age